Biotech companies are always searching for new ways to fund the costly and uncertain process of drug development and product launch. Over the past several years, synthetic royalty and drug development financings have become an additional option for fundraising, as traditional equity markets have remained challenging. Covington & Burling’s third
Continue Reading Synthetic Royalty and Drug Development Financings – A Funding Structure Growing in Europe
Brent Little
Brent Little helps clients structure and negotiate finance transactions, mergers and acquisitions and other strategic transactions. He advises clients in a number of industries, including sports, life sciences, healthcare, technology, consumer products, and manufacturing.
Brent’s financing experience includes representing lenders, borrowers and investors in a variety of finance transactions, many of which involve cross-border components, including senior secured loans, second lien financings, mezzanine debt, subordinated notes, convertible notes, preferred stock, and structured financings. He regularly advises private investment funds in secured debt, royalty and equity financings to pharmaceutical, medical device and healthcare companies. Brent also frequently advises sports teams and their related stadium and holding companies in team, stadium and holding company debt financings.
Brent’s sports transactional experience includes advising buyers and sellers of sports franchises and representing teams and owners in equity financings and secondary sales. He also advises sports leagues, teams, and clubs on their naming rights, sponsorships, and various other corporate transactions.
Brent’s pro bono work has included advising nonprofit organizations in financing transactions, including an impact investing firm that makes loans to microfinance institutions and small and growing businesses. Brent has also advised a school for children with autism in licensing an instructional tool for students with social cognition challenges.